Get the Stockscreener App
1.57
1.95%
0.03
After Hours:
1.70
0.13
+8.28%
Chemomab Therapeutics Ltd Adr stock is traded at $1.57, with a volume of 120.60K.
It is up +1.95% in the last 24 hours and down -22.28% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
See More
Previous Close:
$1.54
Open:
$1.51
24h Volume:
120.60K
Relative Volume:
0.50
Market Cap:
$22.69M
Revenue:
-
Net Income/Loss:
$-33.08M
P/E Ratio:
-0.534
EPS:
-2.94
Net Cash Flow:
$-25.68M
1W Performance:
-0.95%
1M Performance:
-22.28%
6M Performance:
+101.54%
1Y Performance:
+75.42%
1-Day Range:
$1.51
$1.78
1-Week Range:
$1.51
$1.78
52-Week Range:
$0.42
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News
CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com
Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News
CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update - GlobeNewswire Inc.
Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News
Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News
Chemomab regains Nasdaq compliance with bid price rule - Investing.com
Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News
Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News
CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Chemomab secures $10 million in PIPE financing - Investing.com India
Chemomab secures $10 million in PIPE financing - Investing.com
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference - GlobeNewswire Inc.
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - GlobeNewswire Inc.
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
New Strong Sell Stocks for March 14th - Yahoo Canada Shine On
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 - GlobeNewswire Inc.
LGVN Stock Quote Price and Forecast - CNN
Chemomab secures new European patent for liver disease treatment - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC - Yahoo Finance
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):